Brown Advisory’s ImmunityBio IBRX Stock Holding History

Brown Advisory’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$153K	Sell	17,420 -2,381	-12%	-$18K	﹤0.01%	1414
2026 Q1	$152K	Buy	19,801 +7,075	+56%	+$48.4K	﹤0.01%	1352
2025 Q4	$25.2K	Buy	+12,726	New	+$28.8K	﹤0.01%	1376

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brown Advisory's IBRX Position: Q2 2026 in Review

Brown Advisory reduced its ImmunityBio (IBRX) stake by 12% in Q2 2026, selling an estimated $18K and leaving 17,420 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #1414.

Brown Advisory first reported a position in IBRX in Q4 2025 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Brown Advisory held 17,420 shares of ImmunityBio worth $153K as of Q2 2026.
Brown Advisory sold 2,381 ImmunityBio shares in Q2 2026, an estimated $18K.
ImmunityBio made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #1414 holding.
Brown Advisory first reported a position in ImmunityBio in Q4 2025 and has held it in 3 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.